Australia - English - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - meloxicam -

Australia - English - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - omeprazole -

Australia - English - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - amoxycillin trihydrate; amoxycillin -

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - losartan potassium 100mg - film coated tablet - 100 mg - active: losartan potassium 100mg excipient: colloidal silicon dioxide isopropyl alcohol lactose magnesium stearate   methylene chloride microcrystalline cellulose   opadry white 20h58983 pregelatinised maize starch   purified talc - ranbaxy-losartan is indicated for the treatment of hypertension. ranbaxy-losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy ranbaxy-losartan is indicated for the treatment of heart failure in patients who cannot tolerate an ace inhibitor. switching patients with heart failure who are stable on an ace inhibitor to ranbaxy-losartan is not recommended. ranbaxy-losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - losartan potassium 12.5mg - film coated tablet - 12.5 mg - active: losartan potassium 12.5mg excipient: colloidal silicon dioxide isopropyl alcohol lactose magnesium stearate   methylene chloride microcrystalline cellulose   opadry white 20h58983 pregelatinised maize starch   purified talc - ranbaxy-losartan is indicated for the treatment of hypertension. ranbaxy-losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy ranbaxy-losartan is indicated for the treatment of heart failure in patients who cannot tolerate an ace inhibitor. switching patients with heart failure who are stable on an ace inhibitor to ranbaxy-losartan is not recommended. ranbaxy-losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - losartan potassium 25mg - film coated tablet - 25 mg - active: losartan potassium 25mg excipient: colloidal silicon dioxide isopropyl alcohol lactose magnesium stearate   methylene chloride microcrystalline cellulose   opadry white 20h58983 pregelatinised maize starch   purified talc - ranbaxy-losartan is indicated for the treatment of hypertension. ranbaxy-losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy ranbaxy-losartan is indicated for the treatment of heart failure in patients who cannot tolerate an ace inhibitor. switching patients with heart failure who are stable on an ace inhibitor to ranbaxy-losartan is not recommended. ranbaxy-losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - losartan potassium 50mg - film coated tablet - 50 mg - active: losartan potassium 50mg excipient: colloidal silicon dioxide isopropyl alcohol lactose magnesium stearate   methylene chloride microcrystalline cellulose   opadry white 20h58983 pregelatinised maize starch   purified talc - ranbaxy-losartan is indicated for the treatment of hypertension. ranbaxy-losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy ranbaxy-losartan is indicated for the treatment of heart failure in patients who cannot tolerate an ace inhibitor. switching patients with heart failure who are stable on an ace inhibitor to ranbaxy-losartan is not recommended. ranbaxy-losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine, end stage renal disease (need for dialysis or renal transplantation) or death; and to reduce proteinuria.

Australia - English - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - lisinopril dihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - meropenem trihydrate, quantity: 570 mg (equivalent: meropenem, qty 500 mg) - injection, powder for - excipient ingredients: sodium carbonate - meropenem ranbaxy is indicated for the treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: - community acquired lower respiratory tract infection, - hospital acquired lower respiratory tract infection, - complicated urinary tract infection, - febrile neutropenia, - intra-abdominal and gynaecological (polymicrobial) infections, - complicated skin and skin structure infections, - meningitis, - septicaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - meropenem trihydrate, quantity: 1140 mg (equivalent: meropenem, qty 1 g) - injection, powder for - excipient ingredients: sodium carbonate - meropenem ranbaxy is indicated for the treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: - community acquired lower respiratory tract infection, - hospital acquired lower respiratory tract infection, - complicated urinary tract infection, - febrile neutropenia, - intra-abdominal and gynaecological (polymicrobial) infections,- complicated skin and skin structure infections, - meningitis, - septicaemia.